Table 4

Results from structural sensitivity analyses (discounted)
a: Extreme scenarios and variations in the duration of stable VE
Base-case Extreme scenario
Best case Worst case
ICER by outcome
€/HZ-case avoided 1,419 17 4,595
€/PHN-case avoided 20,809 163 327,691
€/QALY gained 28,146 235 157,845
b: Duration of stable VE [years]
0 5 10 (base-case) 15 20
ICER by outcome
€/HZ-case avoided 2,633 1,800 1,419 1,225 1,123
€/PHN-case avoided 40,300 27,057 20,809 17,708 16,128
€/QALY gained 53,702 36,211 28,146 24,060 21,931
c: Booster scenarios [by age at vaccination in years]
Base-case Best case
50 60 70 80
ICER by outcome
€/HZ-case avoided 1,419 1,080 1,361 2,701 9,372
€/PHN-case avoided 20,809 19,001 19,632 22,931 35,604
€/QALY gained 28,146 30,241 32,173 46,126 93,497
Base-case Worst case
50 60 70 80
ICER by outcome
€/HZ-case avoided 1,419 1,580 1,621 2,792 9,384
€/PHN-case avoided 20,809 29,095 22,643 23,345 35,619
€/QALY gained 28,146 52,628 39,604 47,559 93,565
d: Variations in the length of PHN [month]
6 9 (base-case) 15 36
ICER by outcome
€/QALY gained 31,741 28,146 23,048 4,149

, Euro in 2010 price level.ICER, incremental cost-effectiveness ratio; HZ, herpes zoster; PHN, postherpetic neuralgia; QALY, quality adjusted life-year; VE, vaccine efficacy.

Ultsch et al.

Ultsch et al. BMC Health Services Research 2013 13:359   doi:10.1186/1472-6963-13-359

Open Data